معرفی
Tobias Berg is an Associate Professor of Oncology at McMaster University, affiliated with the Juravinski Cancer Centre (JCC) and the Centre for Discovery in Cancer Research (CDCR). He leads the Translational Oncology Program, bridging clinical practice and basic research. His work focuses on understanding treatment resistance and relapse mechanisms in Acute Myeloid Leukemia (AML), leveraging epigenetic regulators, metabolic studies, and stem cell transplantation. Key roles include:
- Member of the Stem Cell and Cellular Therapy Program, specializing in allogeneic transplants and CAR T-cell therapy
- Principal investigator in clinical trials involving LSD1 inhibitors, venetoclax, and sorafenib
- Recipient of funding from the Boris Family Chair for Leukemia Research, Canadian Foundation for Innovation, and OICR
Research Interests: Berg's lab investigates epigenetic drivers of leukemia relapse post-transplant, novel combination therapies, and biomarkers for early disease detection. Techniques include single-cell sequencing, metabolic profiling, and functional in vitro/in vivo models. His work also addresses residual disease detection through standardized flow cytometry panels (HARMONIZE initiative).
Key Trends in Publications: Recent studies highlight:
- Role of IRF8 and LSD1 in AML drug sensitivity
- Impact of mixed donor chimerism on transplant outcomes
- Mechanisms linking metabolism and therapy resistance in FLT3-ITD AML
Grants & Collaborations: Leads multicenter trials (e.g., SORMAIN and TRANSATRA) and collaborates with institutions like the Ontario Institute for Cancer Research. His lab is part of the McMaster Cancer Research Stem Cell Bank, collecting patient-derived samples for translational studies.
